AbbVie partners with Caraway to develop therapies for Parkinson’s disease
Therapeutic caraway and AbbVie have entered into a collaboration agreement to develop and commercialize a small molecule targeting a potassium ion channel implicated in Parkinson’s disease (PD) and other neurodegenerative conditions.
The target, TMEM175, showed strong genetic support under these conditions, making it a key area for research and development. Previous data shows, for example, that loss-of-function mutations in TMEM175 correlate with reduced efficiency of lysosomal function in some patients with PD.
Caraway Therapeutics CEO Martin D. Williams noted in a declaration that TMEM175 variants “which reduce lysosomal function are very common genetic risk factors for the development of PD and the evidence suggests that patients with reduced TMEM175 function tend to have an earlier age of onset. disease and an increased risk of dementia ”.
Caraway, a portfolio company of AbbVie Ventures, plans to continue advancing its proprietary small molecule modulators for Target as part of the new collaboration. The company will use its drug discovery platform and build on its expertise in lysosomal biology and cell clearance mechanisms. Together, AbbVie will bring its expertise in disease biology, clinical development and global commercialization.
“TMEM175 is a compelling genetically validated target for which Caraway has developed a promising drug discovery program,” Eric Karran, Ph.D., AbbVie vice president of neuroscience discovery, said in a statement. “Collaborating with Caraway to advance TMEM175 modulators has great potential to adapt to AbbVie’s efforts to develop transformative treatments for patients with neurodegenerative diseases. “
The terms of the deal give Caraway an upfront cash payment of $ 17 million from AbbVie. Upon completion of certain preclinical research and development activities on behalf of Caraway, AbbVie will have the opportunity to license the program and advance it in new drug research studies, clinical development as well as commercialization. .
In total, the collaboration allows Caraway to receive up to $ 267 million in payouts, including both upfront and future option payouts as well as development milestones. In addition, the company is also eligible for additional regulatory and commercial milestones and tiered royalties on global sales. Caraway also had the opportunity to participate in product development in exchange for a rate increase on future royalties.
Earlier this year, AbbVie also ad a collaboration with Caribou biosciences valued at $ 40 million in upfront cash and equity payments to develop chimeric antigen receptor (CAR) -T therapies. Under terms of this collaboration, AbbVie has agreed to provide an additional $ 300 million in potential milestone payments.
Caribou has been granted the reasonableness of preclinical research, development, and initial manufacture of a total of two standard CAR T cell therapies. In turn, AbbVie will reimburse the pharmaceutical company for the costs of this R&D and manufacturing.
AbbVie continued its series of collaborations with its contribution of $ 90 million in initial capital and equity to support the recent launch of Capsida Biotherapeutics. Capsida focuses on next-generation gene therapies and plans to use AbbVie’s capital to develop tissue-targeted gene therapies for up to three central nervous system disease targets. The company was also launched with additional $ 50 million Series A funding from Versant Ventures and Westlake Village BioPartners.
Featured Jobs on BioSpace